Seres Therapeutics, Inc. 8-K

What Happened

• Seres Therapeutics, Inc. (MCRB) announced its financial results and operational updates for the quarter ended March 31, 2026. The company issued a press release on May 5, 2026, and furnished the full text of that release as Exhibit 99.1 to the Form 8‑K (Item 2.02).

Key Details

• Filing date: May 5, 2026 (Current Report on Form 8‑K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit furnished: 99.1 (press release issued May 5, 2026).
• Interactive data: Exhibit 104 — Cover Page Interactive Data File (embedded Inline XBRL).

Why It Matters

• The 8‑K signals Seres has publicly disclosed its most recent quarterly performance and operational status; the press release will contain the headline financial and operational figures investors watch (earnings, revenue, cash/runway, program updates).
• Investors should read the furnished press release and expect more detailed financial statements and management discussion in the company’s upcoming quarterly SEC filings (e.g., Form 10‑Q) to assess impacts on valuation and near‑term prospects.